Drugmakers are working on seven new treatments for bacteria that resist even the strongest antibiotics, according to a report from the Infectious Diseases Society of America. The IDSA called for more research funding, an improved regulatory climate and economic incentives for drugmakers working on superbug treatments. The antibiotic pipeline "is on life support," IDSA President Dr. David Relman said in a statement.

Full Story:

Related Summaries